Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €42.56 EUR
Change Today +0.03 / 0.07%
Volume 170.0
SGT On Other Exchanges
Symbol
Exchange
Berlin
As of 3:24 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

seattle genetics inc (SGT) Snapshot

Open
€42.23
Previous Close
€42.53
Day High
€43.49
Day Low
€42.23
52 Week High
06/24/15 - €43.85
52 Week Low
10/15/14 - €24.00
Market Cap
5.3B
Average Volume 10 Days
30.8
EPS TTM
--
Shares Outstanding
124.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SEATTLE GENETICS INC (SGT)

seattle genetics inc (SGT) Related Businessweek News

View More BusinessWeek News

seattle genetics inc (SGT) Details

Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Its lead product, ADCETRIS (brentuximab vedotin), is an ADC that is commercially available in approximately 50 countries, including the United States, Canada, Japan, and members of the European Union for relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL) in collaboration with Takeda Pharmaceutical Company Limited. The company is evaluating ADCETRIS in approximately 30 ongoing clinical trials, including Phase III trials for post-transplant HL relapse prevention, relapsed CD30-positive cutaneous T-cell lymphoma, frontline HL in combination with chemotherapy, and frontline CD30-positive mature T-cell lymphoma in combination with chemotherapy, as well as in Phase I and II studies in various lymphoma and non-lymphoma indications. In addition, it is developing a pipeline of other clinical-stage programs, including SGN-CD19A for CD19A-positive hematologic malignancies; SGN-CD33A in CD33-positive acute myeloid leukemia; SGN-LIV1A in LIV-1-positive breast cancer; ASG-22ME for the treatment of Nectin-4-positive solid tumors; ASG-15ME for treatment of SLITRK6-positive bladder cancer; and SEA-CD40, a non-fucosylated antibody utilizing a novel immuno-oncology technology. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie, Bayer, Genentech, GlaxoSmithKline, and Pfizer. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

657 Employees
Last Reported Date: 02/27/15
Founded in 1998

seattle genetics inc (SGT) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $759.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $422.1K
Chief Operating Officer
Total Annual Compensation: $472.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $448.0K
Executive Vice President of Technical Operati...
Total Annual Compensation: $378.4K
Compensation as of Fiscal Year 2014.

seattle genetics inc (SGT) Key Developments

Seattle Genetics, Inc. Announces the Resignation of Srinivas Akkaraju from the Board as Class I Director

On June 18, 2015, the Board of Directors of Seattle Genetics, Inc. among the three classes of the Company's classified Board, Srinivas Akkaraju, M.D., Ph.D., age 47, resigned from the Board as a Class I director and, upon the recommendation of the Nominating and Corporate Governance Committee of the Board.

Seattle Genetics and Unum Therapeutics Enter into Strategic Cancer Immunotherapy Collaboration

Seattle Genetics, Inc. and Unum Therapeutics announced that the two companies have entered into a strategic collaboration and license agreement to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer. Unum's proprietary ACTR technology enables programming of a patient's T-cells to attack tumor cells when co-administered with tumor-specific therapeutic antibodies. Seattle Genetics, through its extensive work in the field of antibody-drug conjugates (ADCs), has a substantial portfolio of cancer targets and tumor-specific monoclonal antibodies from which programs will be selected for the collaboration. Under the terms of the agreement, Seattle Genetics will make an upfront payment of $25 million and an equity investment of $5 million in Unum's next round of private financing. The companies will initially develop two ACTR products incorporating Seattle Genetics antibodies, and Seattle Genetics has an option to expand the collaboration to include a third ACTR product. Unum will conduct preclinical research and clinical development activities through phase 1 with funding from Seattle Genetics. The companies will work together to co-develop and jointly fund programs after phase 1 unless either company opts out. Seattle Genetics and Unum will co-commercialize and share profits 50/50 on any co-developed programs in the United States. Seattle Genetics will retain exclusive commercial rights outside of the United States, paying Unum high single to mid-double digit royalties on ex-U.S. sales. Potential option fee and progress-dependent milestone payments to Unum under the collaboration may total up to $615 million across all three ACTR programs.

Seattle Genetics Highlights ADCETRIS Data Presentations in the AETHERA Post-Transplant Consolidation Setting and in Frontline DLBCL at ASCO Annual Meeting

Seattle Genetics, Inc. announced several ADCETRIS (brentuximab vedotin) data presentations in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma (HL) and in frontline diffuse large B-cell lymphoma (DLBCL) at the American Society of Clinical Oncology Annual Meeting being held May 29 to June 2, 2015, in Chicago, IL. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma (sALCL) and several other types of non-Hodgkin lymphoma. Multivariate analysis of PFS from the AETHERA trial: A phase 3 study of brentuximab vedotin consolidation after autologous stem cell transplant for HL. Data were reported from a multivariate analysis of the effects of demographics, baseline disease characteristics and other risk factors on progression-free survival (PFS) from the phase 3 AETHERA clinical trial. After adjusting for several clinical factors in a multivariate regression analysis, consolidation treatment with ADCETRIS was significantly associated with improved PFS compared with placebo (hazard ratio of 0.44) and was more important, or as important, as all evaluated clinical factors. Results show consistent PFS benefit of ADCETRIS consolidation therapy, regardless of the clinical factors, further supporting ADCETRIS use as consolidation in HL patients following autologous stem cell transplant (ASCT). ADCETRIS is currently not approved for use in the AETHERA treatment setting. Based on the positive results from the AETHERA trial, a supplemental Biologics License Application (BLA) for ADCETRIS in the AETHERA setting for the post-ASCT consolidation treatment of HL patients at high risk of relapse or progression was accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA granted Priority Review for the application and the Prescription Drug User Fee Act (PDUFA) target action date is August 18, 2015. Interim results were reported from an ongoing phase 2 clinical trial evaluating ADCETRIS in combination with the standard of care regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP) in frontline high-intermediate or high-risk DLBCL. Patients were randomized to receive standard dose RCHOP with either 1.2 milligrams per kilogram (mg/kg) (30 patients) or 1.8 mg/kg (23 patients) of ADCETRIS. The trial was designed to assess antitumor activity and the safety profile of ADCETRIS plus RCHOP in these patients. Data were reported from 53 patients with a median age of 67 years. Nearly all (96 percent) had stage III/IV disease and were considered high-risk (38 percent) or high-intermediate risk (62 percent).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGT:GR €42.56 EUR +0.03

SGT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Genmab A/S kr583.00 DKK +3.50
Insys Therapeutics Inc $36.50 USD +1.00
Medivation Inc $113.56 USD +1.50
MorphoSys AG €64.76 EUR -0.004
Pfizer Ltd/India 1,984 INR +4.00
View Industry Companies
 

Industry Analysis

SGT

Industry Average

Valuation SGT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.7x
Price/Book 28.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEATTLE GENETICS INC, please visit www.seattlegenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.